
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. has demonstrated strong financial performance with a reported quarterly revenue of over $85 million for DefenCath, indicating significant year-over-year growth that has surpassed both expectations and previous guidance. The company has raised its pro-forma revenue guidance for 2025 to over $375 million, reflecting confidence in the continued adoption of DefenCath among dialysis practices and successful integration of recently acquired assets from Melinta. With projected revenues for Q3 2025 estimated at $55 million, complemented by recent forecast improvements, the outlook for sustained growth and cash flow enhancement remains robust.
Bears say
Cormedix Inc. demonstrates several fundamental weaknesses contributing to a negative outlook on its stock. The company is projected to continue incurring net losses until at least the product approval and commercialization of DefenCath, creating uncertainty regarding its financial sustainability. Additionally, significant risks are present, including competition from established heparin solutions, potential concentration risk with a single customer, and unclear future pricing strategies post-TDAPA, all of which could severely impact the company's valuation and market positioning.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares